GentiBio
Kevin is Development Scientist II on the Flow Cytometry Assay Development team where he focuses on flow cytometry development and analytics. He is continually fascinated by the ways engineering meets immunology and protein science in a flow cytometer. Originally from Kansas, Kevin moved around the midwest before coming to Seattle 10 years ago. He spent the previous 4.5 years as a member of the flow cytometry analytical development team at Juno/Celgene/BMS, where he supported critical CAR-T programs, including Breyanzi. Kevin worked in the HVTN lab at Fred Hutch and a CRO in Missouri before moving to Seattle.
This person is not in any offices
GentiBio
GentiBio, Inc., is an early stage biotherapeutics company co-founded by pioneers in Treg biology and synthetic immunology to develop engineered regulatory T cells (EngTregs) programmed to treat autoimmune, alloimmune, autoinflammatory and allergic diseases. GentiBio's proprietary autologous and allogeneic EngTregs platform integrates key complimentary technologies needed to successfully restore immune tolerance and overcome major limitations in existing regulatory T-cell therapeutics. GentiBio is at the forefront of leveraging a unique therapeutic modality that can be used to address the fundamental cause of many diseases that result from overshooting and/or malfunctioning of the immune system.